Lung Cancer Clinical Trials

Showing 2241-2260 of 4,288 trials

Lazertinib 160mg in EGFR T790M NSCLC

NCT05701384

The lazertinib is currently approved as 2nd line T790M mutation-positive NSCLC that failed from either 1st or 2nd generation EGFR TKI. The current recommended dosage is 240mg. Based on the promising clinical efficacy of the dose escalation study, this study is designed to evaluatee the clinical efficacy and safety of 160mg lazertinib.

Lung Cancer Stage IVEGFR T790M

Samsung Medical Center117 participantsStarted Feb 2023

Seoul, MA, South Korea

COMPLETEDPhase 1/2

Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer

NCT02713529

A multi-center Phase 1b/2 study testing the combination of AMG 820 and pembrolizumab in subjects with select advanced solid tumors.

Pancreatic CancerColorectal CancerNon-Small Cell Lung Cancer

AmMax Bio, Inc.117 participantsStarted Apr 2016

Atlanta, Georgia, United States • Boston, Massachusetts, United States • Boston, Massachusetts, United States +12 more locations

UNKNOWN

Radiation Pneumonitis After SBRT for NSCLC

NCT02428049

Aims: 1. Evaluate changes in lung function before and after radiotherapy for patients with NSCLC in stage I-III receiving curatively intended radiotherapy 2. To assess the predictive value of pulmonary function tests for the development of radiation pneumonitis after curative radiotherapy 3. To assess biomarkers in blood samples before, during, and after radiotherapy and correlate to the development of radiation pneumonitis 4. Investigate survival

Lung CancerRadiotherapyLung Function Changes

Sykehuset i Vestfold HF105 participantsStarted Oct 2013

Tønsberg, Norway

Lazertinib 160mg in EGFR T790M NSCLC

Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer

Radiation Pneumonitis After SBRT for NSCLC

Related Searches

A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation

Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

Development and Validation of Nomogram Predicting Survival in Chinese SCLC Patients

Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma

Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer

RW Effectiveness of Capmatinib in Advanced MET-dysregulated NSCLC Included in the French Compassionate Use Program (ATU)

BRAF V600-mutated Lung Carcinoma Treated With the Combination of Dabrafenib-trametinib: a Retrospective Evaluation

Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC

Surufatinib in Combination of Durvalumab and EP/EC in the Firstly-line Treatment of ES-SCLC

Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI

Evaluation of GLR2007 for Advanced Solid Tumors

Almonertinib Plus Metronomic Oral Vinorelbine

Meals on Wheels, the Effect of a Home Food-delivery Service for Cancer Patients

ITIL-168 in Advanced Solid Tumors

Evaluation of Vascular Toxicity of Immune Checkpoint Inhibitors in Patients Head and Neck or Lung Cancer